Christopher R Flowers Selected Research

Doxorubicin (Adriamycin)

4/2024	Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study.
11/2023	A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.
1/2022	Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
1/2022	Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
1/2019	PET-derived tumor metrics predict DLBCL response and progression-free survival.
1/2019	Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.
1/2018	Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma.
11/2017	Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
11/2015	A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.
8/2015	Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christopher R Flowers Research Topics

Disease

68	Neoplasms (Cancer) 04/2024 - 06/2007
41	Lymphoma (Lymphomas) 04/2024 - 06/2007
39	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 05/2024 - 12/2010
36	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 05/2024 - 06/2007
22	Non-Hodgkin Lymphoma (Lymphosarcoma) 05/2024 - 09/2005
22	B-Cell Lymphoma (Lymphoma, B Cell) 04/2024 - 02/2010
13	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 12/2023 - 10/2013
11	Hodgkin Disease (Hodgkin's Disease) 01/2021 - 09/2005
9	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 09/2013
8	Multiple Myeloma 01/2019 - 10/2010
7	Hematologic Neoplasms (Hematological Malignancy) 10/2022 - 08/2011
6	Colorectal Neoplasms (Colorectal Cancer) 01/2017 - 12/2014
5	Inflammation (Inflammations) 01/2023 - 11/2019
5	Leukemia 10/2018 - 01/2007
5	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2018 - 01/2007
4	Venous Thromboembolism 04/2024 - 01/2023
4	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 11/2020 - 05/2015
4	Autoimmune Diseases (Autoimmune Disease) 01/2016 - 08/2014
3	Paralysis (Palsy) 04/2024 - 01/2023
3	Pulmonary Embolism 01/2023 - 06/2013
3	Venous Thrombosis (Deep-Vein Thrombosis) 01/2023 - 06/2013
3	Neutropenia 12/2022 - 03/2014
3	Disease Progression 02/2019 - 02/2016
3	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 07/2015 - 01/2011
2	Hemorrhage 01/2023 - 10/2020
2	Human Influenza (Influenza) 07/2021 - 01/2019
2	Peripheral Nervous System Diseases (PNS Diseases) 10/2020 - 11/2015
2	Fatigue 06/2020 - 10/2013
2	T-Cell Lymphoma (Lymphoma, T Cell) 11/2019 - 07/2015
2	Pneumonia (Pneumonitis) 10/2018 - 03/2014
2	Fever (Fevers) 10/2018 - 02/2013

Drug/Important Bio-Agent (IBA)

44	Rituximab (Mabthera)FDA Link 05/2024 - 10/2009
17	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/2024 - 04/2012
14	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2024 - 04/2012
13	Prednisone (Sone)FDA LinkGeneric 04/2024 - 07/2012
13	Vincristine (Oncovin)FDA LinkGeneric 11/2023 - 04/2012
12	Chimeric Antigen ReceptorsIBA 01/2024 - 01/2018
8	ibrutinibIBA 03/2024 - 01/2017
8	VaccinesIBA 01/2022 - 06/2007
7	polatuzumab vedotinIBA 05/2024 - 10/2020
6	Biomarkers (Surrogate Marker)IBA 11/2022 - 01/2017
5	obinutuzumabIBA 05/2024 - 01/2019
5	AnthracyclinesIBA 04/2024 - 01/2011
5	axicabtagene ciloleucelIBA 11/2023 - 01/2021
5	Alkylating AgentsIBA 11/2023 - 09/2013
5	Lenalidomide (CC 5013)FDA Link 11/2023 - 06/2020
5	CytokinesIBA 01/2023 - 01/2018
5	AntigensIBA 11/2019 - 07/2011
5	Bortezomib (Velcade)FDA Link 11/2017 - 10/2009
4	Bendamustine Hydrochloride FDA Link 09/2023 - 01/2017
4	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 04/2012
4	idelalisibIBA 01/2021 - 03/2014
4	Benzene (Benzole)IBA 01/2020 - 09/2013
4	Etoposide (VP 16)FDA LinkGeneric 01/2016 - 08/2012
4	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 09/2013 - 08/2011
3	Monoclonal AntibodiesIBA 05/2024 - 09/2013
3	venetoclaxIBA 05/2024 - 01/2020
3	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 12/2012
3	Agammaglobulinaemia Tyrosine KinaseIBA 01/2023 - 01/2017
3	AntibodiesIBA 01/2023 - 06/2007
3	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2022 - 04/2012
3	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022 - 02/2013
3	carboxyl radical (COO-)IBA 01/2021 - 01/2019
3	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 10/2020 - 06/2013
3	AnticoagulantsIBA 10/2020 - 06/2013
3	Immunoglobulin Idiotypes (Idiotype, Immunoglobulin)IBA 11/2016 - 06/2007
3	Busulfan (Busulfex)FDA Link 01/2016 - 08/2012
3	fludarabineIBA 11/2015 - 05/2015
3	plerixafor FDA Link 09/2013 - 10/2011
2	zanubrutinibIBA 03/2024 - 11/2023
2	Biological FactorsIBA 01/2024 - 06/2020
2	Immune Checkpoint InhibitorsIBA 01/2023 - 04/2017
2	Proteins (Proteins, Gene)FDA Link 01/2023 - 11/2019
2	InterferonsIBA 01/2023 - 11/2020
2	RNA (Ribonucleic Acid)IBA 01/2023 - 01/2022
2	apixabanIBA 01/2023 - 10/2020
2	RivaroxabanIBA 01/2023 - 10/2020
2	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 04/2012
2	pembrolizumabIBA 01/2022 - 04/2017
2	Influenza Vaccines (Influenza Vaccine)FDA Link 07/2021 - 01/2019
2	RadiumIBA 01/2021 - 01/2021
2	ublituximabIBA 11/2019 - 02/2019
2	umbralisibIBA 11/2019 - 02/2019
2	CarcinogensIBA 11/2019 - 04/2016
2	purineIBA 10/2018 - 09/2013
2	Antiviral Agents (Antivirals)IBA 10/2018 - 10/2011
2	Clindamycin (Cleocin)FDA LinkGeneric 10/2018 - 02/2013

Therapy/Procedure

90	Therapeutics 04/2024 - 01/2007
32	Drug Therapy (Chemotherapy) 01/2023 - 09/2005
13	Stem Cell Transplantation 01/2023 - 09/2005
7	Immunotherapy 01/2023 - 06/2007
6	Transplantation 10/2020 - 01/2007
5	Radiotherapy 01/2021 - 09/2005
4	Salvage Therapy 11/2017 - 12/2013
3	Precision Medicine 01/2020 - 06/2017
3	Hematopoietic Stem Cell Transplantation 10/2018 - 06/2014
3	Hematopoietic Stem Cell Mobilization 09/2013 - 08/2011
2	Injections 01/2023 - 01/2022
2	Combined Modality Therapy 01/2021 - 12/2016
2	Photopheresis 11/2020 - 11/2010